Model clinical parameters
| Result or transition . | Estimate . | Range . | Study or data source . |
|---|---|---|---|
| OS for azacitidine-venetoclax | Weibull: λ = 0.0843388, κ = 0.7800001 | — | 10 |
| EFS for azacitidine-venetoclax | Weibull: λ = 0.079045, κ = 0.9180112 | — | 10 |
| Hazard ratio for OS (azacitidine as reference) | 0.66 | 0.52-0.85 | 10 |
| Hazard ratio for EFS (azacitidine as reference) | 0.63 | 0.49-0.82 | 10 |
| Probability of treatment discontinuation because of AE, % | |||
| Azacitidine-venetoclax | 24 | 12-36 | 10 |
| Azacitidine | 20 | 10-30 | 10 |
| Discontinuation events because of AE occurring within first 2 mo of treatment, % | 50 | 25-75 | Expert opinion |
| Patients receiving growth factor, % | |||
| Azacitidine-venetoclax | 32 | 16-48 | 10 |
| Azacitidine | 0 | 0-16 | Expert opinion |
| No. of doses of growth factor | 5 | 0-10 | Expert opinion |
| Patients experiencing dose interruption after first cycle of treatment, % | |||
| Azacitidine-venetoclax | 72 | 36-100 | 10 |
| Azacitidine | 57 | 29-86 | 10 |
| Median duration of dose interruption, wk | 2 | 0-4 | 22 |
| Patients hospitalized during venetoclax dose ramp-up, % | 20 | 0-100 | Expert opinion |
| Patients achieving TI, % | |||
| Azacitidine-venetoclax | 64 | 32-96 | 10 |
| Azacitidine | 43 | 21-64 | 10 |
| Discount rate, % | 3 | 1.5-6.0 | 19 |
| Result or transition . | Estimate . | Range . | Study or data source . |
|---|---|---|---|
| OS for azacitidine-venetoclax | Weibull: λ = 0.0843388, κ = 0.7800001 | — | 10 |
| EFS for azacitidine-venetoclax | Weibull: λ = 0.079045, κ = 0.9180112 | — | 10 |
| Hazard ratio for OS (azacitidine as reference) | 0.66 | 0.52-0.85 | 10 |
| Hazard ratio for EFS (azacitidine as reference) | 0.63 | 0.49-0.82 | 10 |
| Probability of treatment discontinuation because of AE, % | |||
| Azacitidine-venetoclax | 24 | 12-36 | 10 |
| Azacitidine | 20 | 10-30 | 10 |
| Discontinuation events because of AE occurring within first 2 mo of treatment, % | 50 | 25-75 | Expert opinion |
| Patients receiving growth factor, % | |||
| Azacitidine-venetoclax | 32 | 16-48 | 10 |
| Azacitidine | 0 | 0-16 | Expert opinion |
| No. of doses of growth factor | 5 | 0-10 | Expert opinion |
| Patients experiencing dose interruption after first cycle of treatment, % | |||
| Azacitidine-venetoclax | 72 | 36-100 | 10 |
| Azacitidine | 57 | 29-86 | 10 |
| Median duration of dose interruption, wk | 2 | 0-4 | 22 |
| Patients hospitalized during venetoclax dose ramp-up, % | 20 | 0-100 | Expert opinion |
| Patients achieving TI, % | |||
| Azacitidine-venetoclax | 64 | 32-96 | 10 |
| Azacitidine | 43 | 21-64 | 10 |
| Discount rate, % | 3 | 1.5-6.0 | 19 |
AE, adverse event.